• Friendable and Santo Blockchain Labs and Mining Corp. working together for the development of global entertainment and musical artist-driven non-fungible tokens, along with the development of a “Fanpasscrypto” marketplace
• Each NFT is a unique opportunity for a new revenue stream for artists and the two companies
• While the Union of Musicians and Allied Workers (“UMAW”) is bringing grievances against streaming platforms like Spotify and Apple Music, Fan Pass continues to seek and incorporate ways for artists to receive revenue

A non-fungible token (“NFT”) is not a form of cryptocurrency (or a form of monetary value), but represents a digital certification of the value of an item that lives on the blockchain. NFTs create digital contracts, proof of ownership, proof of authenticity, certification, also any other items and business rules that are related to the item, attaching to them through its lifespan – defining what it is and the value it holds. Each NFT is unique based on the information stored in the token’s metadata, including token ID that points to the artwork, image, web domain, or another valuable digital resource. This new form of digital ownership is being leveraged by mobile technology and marketing company Friendable (OTC: FDBL) to enhance its Fan Pass platform offering to artist members and their fans. Recently, Friendable has signed a Letter of Intent (“LOI”) with Santo Blockchain Labs and Santo Mining Corp. (OTC: SANP) for the development of global entertainment and musical artist-driven NFTs, as well as the development of the “Fanpasscrypto” marketplace. Each NFT created is a unique opportunity for a new revenue stream for artists and the two companies. Friendable’s NFTs will be unique and may represent both digital and/or augmented reality images. The NFTs themselves may be images of the entertainers or customized to offer exclusive merchandising and interactions. There are multiple ways for the company to monetize, which may also open the doors for opportunities with brand sponsors and retail brands. “It’s been three long years since the inception of our flagship crypto code SKULLYS. We are proud to bring over 100,000 lines of unique code to the outstanding team over at Fan Pass. With the rise of blockchain and NFT technology, the future is only limited by our imagination,” Santo Blockchain Labs CEO Frank Yglesias said about the deal (https://ibn.fm/9sxbB). SKULLYS are a line of reward-based digital collectibles found on the blockchain that uses a specially embedded “pirate code” proprietary to the Santo – A.R.R. (Accept, Relinquish, Reward). Even with the upcoming NFT offering, Fan Pass is still finding ways to reward and incentivize artists, while other streaming companies are facing complaints over their revenue structures. Platforms like Apple and Spotify are taking heat because of how artist royalty distribution is handled. When monthly fees are paid, they are distributed starting with the most popular artist’s royalties and trickling down the ecosystem. Even with the push back from the Union of Musicians and Allied Workers (“UMAW”), there is skepticism that the streaming industry can be shaped to conform to every artist’s liking. Fan Pass has a payment structure for artists that allows them to take a cut of the monthly subscription costs, but also additional forms of revenue, including ticket sales for VIP events, monthly contests, merchandise, and NFTs in the future. Each month, Fan Pass also rewards the top artists and those who are new to the platform. These are only the beginning of what artists will be able to do on the Fan Pass platform as a means of earning a living in the post-pandemic world. Fan Pass also offers premium services that help new and existing artists with merchandise, marketing, and other foundational attributes of their craft. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

• Musicians have had to find ways to adapt their crowd-based revenue streams to the restrictive conditions of the ongoing pandemic
• Several artists have turned to Internet-accessible events to keep the paychecks coming in, adapting their royalty models to those conditions
• To show musicians there may be a different way to profit from their royalties BAND Royalty has acquired the performance royalties of songs performed by Justin Timberlake, Timbaland, Rihanna, Beyonce, Cher, Demi Lovato and other multi -platinum performers and  are developing a way to connect these royalties to collectible digital art, NFTs, that can be used in a unique DeFi product that lets NFT holders access a piece of the music royalty revenues.
• The NFTs brought in the Ethereum equivalent of over $700,000 during a presale May 5. On May 17^th, 2021 Band Royalty released the first ever Music NFT only platform on their website. Available for sale are the remaining 2000 NFTs, starting at 1 ETH, directly on their website.

Among the harmful effects of the pandemic on economies worldwide is the shutdown of public performance venues such as concert stadiums where artists have the ultimate opportunity to connect with fans and influence not only sales, but some measure of cultural conception. A study by global entertainment ticketing company Live Nation in 2018, prior to the pandemic’s outbreak, found that among respondents in the United States, Canada, Mexico, Brazil, United Kingdom, Germany, France, Scandinavia, China, Japan and Australia, 72 percent of Gen Z / Millennial audiences have driven over 100 miles to go to a live music event, two-thirds of Gen X, Y, and Z attend at least one concert or festival each year, that a majority of them go to multiple such events each year, and that 78 percent reported feeling high emotional intensity. Overall, the respondents rated their musical preferences as having a greater import on defining them as a person than their hometown, politics, race or religion (https://ibn.fm/PgD6d). During the course of the pandemic, a number of artists have adapted by performing goodwill as well as for-profit events online in an effort to adapt to the health code restrictions imposed by governments around the globe, remain on fans’ radars and keep revenues flowing (https://ibn.fm/74885). The efforts highlight the importance of tailoring the royalty payment model to ever-changing circumstances in the industry. BAND Royalty, a company devoted to music industry innovations wants to use NFTs and DeFi principles that increase transparency and engagement between artists and their fans.  They have history in the music monetization sector recently with its non-fungible token (“NFT”) product that pairs premier works of digital art with DeFi access to revenue streams from music performed by select artists including Beyoncé, Justin Timberlake, Rihanna, will.i.am and Jay-Z. NFTs are comparable to collectibles that fans can buy, trade or simply store and admire, whose potential monetary value may increase over time according to their rarity and persistent appeal. BAND’s model revolutionizes the DeFi sector by making the NFTs stakeable in royalty pools that effectively allow NFT holders to receive a percentage of the revenue from various artists’ works. In a pre-sale a couple hundred BAND NFT collectibles sold for a combined cryptocurrency value of over $700,000 in Ethereum equivalence to select buyers on May 5. With the unsold NFT collectibles becoming available on Band Royalty’s first ever Music NFT marketplace, on May 17 for general public purchase on a first-come, first-served basis (https://ibn.fm/1Ajvn). Additional series of BAND NFT collectibles and a band token launch will be rolled out later this year. The staked NFTs are granted access to revenues from a shared percentage of the songwriter’s “writer rights,” which, when paired with the publisher’s share, comprise the primary two components of music intellectual property (“IP”) rights and royalties (https://ibn.fm/6EwXq). Under BAND’s royalty shares model, the NFT holder can choose whether to pit the value of the NFT on a temporary basis against potential royalties that might be derived from a choice of three channels — publishing of a musical selection, public and mechanical performances of the musical selection, or visual media synchronization of the selection such as its appearance in a movie, video game or advertisement. For more information, visit the company’s website at www.BANDRoyalty.com. NOTE TO INVESTORS: The latest news and updates relating to BAND Royalty are available in the company’s newsroom at https://ibn.fm/BAND

• Tryp Therapeutics is a pharmaceutical company focused on developing new potential treatments for medical conditions with unmet needs
• The company’s current lead candidates for drug development are a synthetic psychedelic for treating fibromyalgia and eating disorders
• Tryp’s efforts to develop a psychedelic drug candidate are part of a broader scientific movement to use various mind-altering drugs to treat select neurological conditions when paired with the care of a trained therapist
• The company has been preparing to initiate a Phase 2a clinical trial for the psychedelic candidate in partnership with a medical research team at the University of Florida

The idea of using psychedelic, mind-tripping drugs as pharmaceuticals to help improve the quality of people’s lives no longer seems as far out as it once might have during the heyday of the multinational war on drugs. An increasing cadre of investigational science efforts are utilizing psychedelics to determine their potential in creating better medicine for select conditions with neurological-based maladies.

San Diego-based pharmaceutical company Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is turning its own investigational machinery toward the development of drug candidates TRP-8802, a synthetic psilocybin formulation being aimed at fibromyalgia and certain eating disorders.

The development of TRP-8802 is taking place under Tryp’s trademarked Psilocybin-for-Neuropsychiatric Disorders (PFN(TM)) program, which is also evaluating the potential of synthetic psilocybin for treating neuropsychiatric-based chronic pain conditions and eating disorders, such as binge eating and hypothalamic obesity.

The company is partnering with the University of Florida and lead investigator Jennifer Miller, M.D., for a Phase 2a clinical trial looking into TRP-8802’s safety and efficacy in treating eating disorders.

“The research we’re actually going to be doing at the University of Florida with psilocybin is focusing on a little bit more intense problems than just eating disorders,” Dr. Miller said during an interview with The Dales Report published May 3 (https://ibn.fm/F4kho). “Ultimately, of course, we hope it will help people with overall eating disorders, but first we’re going to focus on people with specific neurologic causes of those eating disorders, primarily something called hyperphagia, where (the patients) just never feel full, so they are constantly wanting to eat.”

Dr. Miller, a professor of pediatrics and endocrinology at the University of Florida, said researchers will look at the efficacy in treating people with uncontrollable eating urges resulting from the genetic disorder PWS, hypothalamic obesity eating disorder resulting from the removal of a brain tumor, and binge eating disorder.

“All of the currently available approved obesity and eating disorder medications are daily medications: you stop taking them, you stop having the efficacy,” Miller said. “Our hope is with psilocybin, … (that) once- or twice-a-year treatments will allow these neural networks to rewire themselves and provide a more chronic treatment, which doesn’t exist right now. … None of the currently available treatments or even past available treatments touch their appetite and fullness.”

Tryp’s ambitions are being fueled by other institutions’ recent studies into psychedelics’ benefits and efforts to open legislative avenues for broader legal use of psychedelics in wellness programs.

Science magazine hailed study results published earlier this month that indicated ecstasy (the compound 3,4-methylenedioxymethamphetamine, or MDMA) alleviated post-traumatic stress disorder (“PTSD”) in a phase 3 clinical trial, branding them a “milestone in efforts to turn psychedelic drugs into mainstream treatments,” particularly because it involved administering a mind-altering drug under the care of a trained therapist (https://ibn.fm/HDaqz).

In the United Kingdom, a recent documentary examined a study by renowned neuropsychopharmacologist David Nutt into uses of psilocybin as a potentially better treatment for depression than commonly prescribed medications (https://ibn.fm/Gcuuy). and researchers at the University of California, Davis report they have achieved a medical breakthrough with their discovery of a psychedelic molecule that doesn’t trigger hallucinations (https://ibn.fm/RLCrm).

In regard to the eating disorders stay at the University of Florida, Tryp President and Chief Science Officer Jim Gilligan, Ph.D. told The Dales Report, “What Tryp is supplying is the psychedelic expertise as a complement … We take luminaries in the field, such as Dr. Miller in eating disorders, and pair with Tryp, and we think that gives us the best likelihood of a positive outcome.”

Gilligan added, “What we’d like to be able to do is, in a way, demystify … and show that, ‘Look, there’s good clinical data’; there’s good reason to believe that there’s an opportunity to do this, and I think the more groups that have success across the spectrum, the better off we’re going to be.”

For more information, visit the company’s website at www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

 

• FingerMotion, a U.S.-based communications technology company focused on China’s enormous marketplace, is steadily building partnerships to help it grow a potential for a billion users
• The company’s latest contract is with China Mobile Fujian, a provincial mobile information service operator
• FingerMotion expects the volume-based SMS agreement to boost its gross profit margin by about 30 percent and potentially lead to additional, similar agreements
• FingerMotion also demonstrated its promise when it secured a collaborative agreement with insurance titan Pacific Life Re that will allow FingerMotion to serve as Pacific Life’s data provider in China

Mobile data and services innovator FingerMotion (OTCQX: FNGR) has taken another step toward rich communication services (“RCS”) and big-data insights expansion in China’s hot market for data applications this year.

The company, which possesses one of only a handful of licenses to access and analyze the mobile data of telecommunications giants China Unicom and China Mobile customers, announced May 18 that it has entered an agreement with China Mobile Fujian that is expected to bring about 30 percent improvement to FingerMotion’s gross margin on its SMS (message texting) business, according to the announcement (https://ibn.fm/kdy9l).

China Mobile Fujian has about 30 million or more online subscribers, which is about 70 percent of the market share in the province of Fujian. The announcement states that large provincial mobile information service operators in China are provisioning resources to take advantage of a marketplace anticipating rapid growth with the introduction of 5G wireless networks, and they may look to FingerMotion SMS subsidiary JiuGe “for guidance and assistance.”

JiuGe was a key part of the contract negotiations between FingerMotion and China Mobile Fujian and expects to continue to secure new contracts with China Mobile. China Mobile and China Unicom’s customer base represents over 1.1 billion phones.

“Our focus over the past year was on improving margins,” FingerMotion CEO Martin Shen stated. “This volume-based agreement is expected to increase our margins from 6.1% to approximately 30% and is a testament to our incredibly talented team that continues to impress our business partners. With SMS demand remaining strong, we are able to meet the new pressures through operational efficiencies but continue to be limited by the capital required to adequately fund operations.”

FingerMotion’s core competency is in mobile payment and recharge platform solutions in China, but as the user base of its primary business continues to grow the company is bringing new value-added technologies to market in order to establish an ecosystem of users with high engagement rates.

The availability of more than a billion Chinese consumers’ data to FingerMotion drew the attention of insurance industry giant Pacific Life’s reinsurance division, which sealed a collaborative agreement with FingerMotion in January that essentially makes FingerMotion the data provider for Pacific Life as it looks for growth opportunities in the Chinese insurance industry (https://ibn.fm/cC2nu).

The data services provided by FingerMotion will be able to serve as a proxy for a credit score system in the country. FingerMotion’s Sapientus database helps derive predictive behavior analytics from the data the company obtains to anticipate consumer habits.

The company expects to file its year-end financial report by the end of the month, and predicts annual revenues will top $16 million (https://ibn.fm/LrTPG).

For more information, visit the company’s website at www.FingerMotion.com.

NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

 

• Asia Broadband Inc., an experienced producer of precious metals is adding key gold mine property acquisitions in Mexico, while concurrently developing a proprietary cryptocurrency exchange
• The exchange will build a mechanism for holders of its gold-backed AABBG token to trade with major cryptocurrencies such as Bitcoin, Ethereum, and Litecoin
• The AABBG tokens launched in March, backed by $30 million in physical gold from the company’s properties
• The company reports it achieved several milestones in regard to the exchange’s development during the past month that were related to its network, platform, design and algorithms
• Asia Broadband expects to test the exchange in August and go live with it in September

Asia Broadband (OTC: AABB), a precious and base metals producer intent on developing a proprietary cryptocurrency exchange following the launch of its gold-backed AABBG cryptocurrency token, is reporting progress on the exchange’s creation. The company is backing its entry with $30 million in physical gold from its properties in Mexico, with the price of each token tied to whatever the existing price of one-tenth (0.1) gram of gold may be plus a 2 percent transaction fee  (https://ibn.fm/xqm2Q).

The AABBG token has dual advantages to purchasers. Though not a “stablecoin”, the token has stablecoin-like stability properties in that it is backed and supported by the company at minimum the .1 gram spot price of gold.  Additionally, the token will also have the price appreciation qualities of typical cryptocurrencies, once the proprietary exchange allows the token to be freely exchangeable.

According to a news release issued May 11 (https://ibn.fm/sU6Y3), the company achieved several milestones during the first month of developing the exchange’s network, platform, design and algorithms. Improvements included adding greater visitor capacity, enabling two-way transfers between the blockchain and the user’s wallet and establishing a more efficient mechanism for adding new currencies, completing the iOS, Android and web version designs, and putting the know your customer (“KYC”) protocols into motion for streamlining user and system processes.

The exchange will allow Asia Broadband wallet users to complete quick, two-way exchanges of their AABBG tokens for major cryptocurrencies such as Bitcoin, Ethereum and Litecoin.

According to the news release, the exchange will also augment transaction fee revenues and make it possible for the price of AABBG to appreciate based on market demand and the limits on the number of tokens in circulation.

Select cryptocurrencies have gained enormous value on the market in recent years despite instability that has seen their values fluctuate, and a growing number of investors has turned to the alternate form of money as a potential source of financial profile increase. Famed investors such as billionaire Stanley Druckenmiller predict that the U.S. dollar is on the verge of losing its status as the world’s reserve currency as the country faces the prospect of having to monetize its debt in order to meet its obligations, and some investors understandably prefer exchanges tethered to physical assets such as gold in order to increase their security and reduce volatility. (https://ibn.fm/PcDJe).

Asia Broadband’s exchange is planned for testing in mid-August and is expected to go live in early September. Before then, the company will work to complete its cold wallet, web versions of the wallet and exchange, transaction fee mechanism, trade platform and reporting system, according to the news release.

The Las Vegas-based company has acquired two mines — one in the Mexican state of Guerrero and another in the state of Colima. Its year-end fiscal report stated the company had a record annual gross profit of $16.8 million during 2020.

For more information, visit the company’s website at www.AsiaBroadbandInc.com.

NOTE TO INVESTORS: The latest news and updates relating to AABB are available in the company’s newsroom https://ibn.fm/AABB

 

• IP attorney Alan M. Weisberg, Esq., a partner of Christopher & Weisberg, to work with company
• HENC committed to ensuring that IP generates maximum return for shareholders
• BlackBox has developed a proprietary cannabis growing system based on aeroponic cultivation technology

Hero Technologies (OTC: HENC), a cannabis company focused on a vertically integrated strategy, announced that it has retained intellectual property attorney Alan M. Weisberg, Esq., a partner of Christopher & Weisberg, P.A. Weisberg will assist and advise the company as it focuses on protecting and monetizing the intellectual property of its subsidiary, BlackBox Systems and Technologies LLC (https://ibn.fm/1BCo9). “Solidifying our cannabis intellectual property rights is essential as we seek to monetize our proprietary growing systems,” said Hero Technologies CEO Gina Serkasevich. “Whether by protecting our competitive advantages—particularly in the cost structure and environmental impact of our cannabis operations—or to potentially license our technology for others to use, we want to ensure that our IP generates maximum return for our shareholders.” A registered patent attorney with more than 30 years of technical experience, Weisberg is a former engineer and consultant for IB and has been a featured presenter for the Daily Business Review‘s Intellectual Property Roundtable. He earned a JD, cum laude, and an MS in information systems from Pace University, and a BSEE degree from the Rochester Institute of Technology. BlackBox has developed a proprietary cannabis growing system based on aeroponic cultivation technology (https://ibn.fm/uqh5r). The system creates ideal cannabis growing conditions with a highly efficient use of materials that increases photosynthesis, produces large plant flowers, and optimizes harvests. The BlackBox system design features a high-pressure nutrient delivery system equipped with a UPS battery back-up. The patented innovations in BlackBox’s grow technology allow for the production of premium-grade cannabis at scale, resulting in increasing margins for both wholesalers and retailers while maintaining the highest consumer standards. Hero Technologies is looking for opportunities to acquire significant greenhouse and warehouse space that it can develop for cannabis cultivation and retail operations. The company plans to use its exclusive BlackBox technology for its cultivation projects. Hero Technologies is a cannabis company working toward a vertically integrated business model. The company owns a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased harvest efficiencies. The company’s strategic business plan includes cannabis genetic engineering, farmland for both medical and recreational cannabis cultivation, production licenses, distribution licenses, consumer packaging, and retail and dispensary operations that make the company a multi-state operator (“MSO”). For more information, visit the company’s website at www.HeroTechnologiesInc.com. NOTE TO INVESTORS: The latest news and updates relating to HENC are available in the company’s newsroom at https://ibn.fm/HENC

• Completed acquisition of Acreage Florida, Inc and related owned and leased real estate assets
• Licensed to operate 35 dispensaries, a processing facility and a cultivation facility in Florida
• Florida cannabis market is poised for tremendous growth and it is forecasted to be a top 5 State by the year 2025

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), the torchbearer for a new, higher standard in the American cannabis industry, has announced its new subsidiary RWB Florida LLC, has completed the acquisition of Acreage Florida, Inc. and the related owned and leased real estate assets (https://ibn.fm/aUG1Q). This deal includes over 15 acres of land, a 114,000 SF facility for cultivation, a 4,000 SF freestanding administrative office building, and eight leased stores in prime locations throughout Florida. RWB is positioning itself to be one of the top three multi-state cannabis operators in the US legal cannabis and hemp market. The Company is on a mission to be the superior and most recognizable cannabis company in the US by holding itself to the highest ethical, manufacturing, education, branding and employment standards. “Our employees are impressed with Red White & Bloom’s commitment to the local communities as they expand their ESO program around the environment, jobs, social justice and governance,” stated Jim Frasier, Florida General Manager for RWB. “We are excited to play a major role in the benefits cannabis can bring to the state of Florida.” The Company is licensed to operate 35 dispensaries, a processing facility, and a cultivation facility in Florida. With 30 double-wide fully enclosed cultivation pods ready to deploy in the state, RWB plans to expedite the opening of additional medical marijuana dispensary locations and the implementation of home delivery (https://ibn.fm/T3R52). “The Florida cannabis market is poised for tremendous growth and is forecasted to be a top 5 State by the year 2025,” said Brad Rogers, CEO of RWB. “With approximately 450,000 medical cannabis patients currently registered in Florida, we see this as an amazing growth opportunity for the Company. Combine this with a population of 20M and we are delighted this deal has been finalized and look forward to delivering the highest quality medical products to the market.” The Company has currently completed or has definitive agreements for acquiring THC licensed entities in Michigan, Illinois, Florida, California, and Massachusetts. Once all acquisitions are completed, RWB will be available in 6 of the top 10 US states. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• AmpliTech was tasked by Amplify My Probe with creating a special cryogenic probe head to facilitate studies on materials, molecules, and drugs
• The probe is expected to help speed up Electron Paramagnetic Resonance experiments by more than 100 times
• AmpliTech will be the exclusive manufacturer for the device, and Amplify My Probe will have sole global distribution rights for at least the first 18 months
• Since uplisting to NASDAQ in February 2021, AmpliTech has raised $30 million, creating a strong balance sheet and cash position for the company and allowing it to stay focused on growth and hedge against future market volatility

AmpliTech Group (NASDAQ: AMPG, AMPGW), a designer, developer and manufacturer of custom and standard state-of-the-art RF components for various markets including commercial, SATCOM, space, defense and military, received a significant developmental order for a special cryogenic probe head used to facilitate studies on materials, molecules, and drugs to treat diseases, among other applications (https://ibn.fm/PYlkm). The order was placed by Amplify My Probe, Ltd., a company that emerged from the Quantum Spin Dynamics group at the London Centre for Nanotechnology and UCLQ, and which specializes in commercializing technology to improve signal to noise ratio in Electron Paramagnetic Resonance (“EPR”) experiments. AmpliTech’s will leverage its proprietary cryogenic low-noise amplifier technology that operates at 5 degrees Kelvin (-450 degrees Fahrenheit), to create the requested probe. The amplifier technology has a low power dissipation and can also be used in quantum computing, nanophysics, and astronomy applications. The exclusive manufacturer for the product will be AmpliTech, with Amplify My Probe having the sole global distribution rights for a term of at least 18 months. Other possible applications include speeding up new drug design, increasing efficiency in catalytic processes, and discovering new materials for future quantum computers. According to Dr. Simenas Mantas, one of the Amplify My Probe team members who designed the EPR cryogenic probe, the device is expected to significantly speed up EPR experiments by amplifying microwave signals and suppressing source noise. We anticipate close to 100x speedup of the experiments. Such an improvement is highly relevant in the field as it will significantly expand the domain of systems that can be studied by EPR. Among such systems are biomolecules, catalytic surfaces, materials for quantum computing and others,” Dr. Mantas added. AmpliTech CEO Fawad Maqbool added that his company was looking forward to working with Amplify My Probe to help develop this innovative new product that will advance materials science and medical technology. “AmpliTech Group, Inc. is dedicated to being a driving force and leader in amplifier technology for communications and microwave applications that are part of everyday life around us,” Maqbool said. This contract has the potential to help strengthen AmpliTech’s position in an expanding market and pave the way to new opportunities for growth in the future. The global market for RF components in 2020 was valued at $23.79 billion, and is expected to grow at a CAGR of 14% through 2025, resulting in an estimated $45.05 billion market (https://ibn.fm/26TSZ). The company has plans to be a facilitator for enhancing, developing, and distributing breakthroughs in the following markets:

• High speed terrestrial and satellite terminals (SATCOM, “Internet in the Sky”)
• IoT (Internet of Things)
• Quantum supercomputers and research
• Autonomous self-driving vehicles
• Drones, AUVs (unmanned aerial vehicles)
• Military and defense ECM/EW
• 5G/Wi-Fi6E and 6G wireless infrastructure (cellular base stations, small cells, private Wi-Fi networks)
• Cloud farms, big data, and MEC architecture
• Deep space astronomy
• Telemedicine, AR/VR (augmented and virtual reality)
• Cybersecurity

AmpliTech recently announced that since the company uplisted to NASDAQ on February 17, 2021, it has raised more than $30 million in capital. The company believes that this is a sign of validation of its strategic growth plan among the investment community (https://ibn.fm/wDoNo). “We are pleased to see the level of interest by so many investors in these capital raises,” Maqbool said. “We have raised this capital to strengthen the Company financially and thus be better positioned to fulfill larger orders and broaden our customer base.” With the proceeds, AmpliTech plans to allocate funding, funneling it into specific endeavors. Among the potential uses of the $30 million raised, the company plans to focus on:

• Funding organic growth by sales force expansion and boosting the business development and marketing efforts,
• Expanding the production capabilities while strengthening the operations team,
• Making strategic acquisitions or acquire complementary intellectual properties,
• Funding additional research and development efforts to sustain continued organic growth, and
• Purchasing capital equipment to increase production efforts for productivity and engineering support.

The current investments into AmpliTech allow the company to pay down debt and use cash (and non-dilutive methods) for M&A activities aimed at building a world that the company envisions sustaining through its proprietary technology designed to improve everyone’s quality of life – whether it be through smart homes, cities, or high-speed 5G connectivity. For more information, visit the company’s website at www.AmpliTechInc.com. NOTE TO INVESTORS: The latest news and updates relating to AMPG are available in the company’s newsroom at https://ibn.fm/AMPG

June 3-4th, 2021 DGE’s Risk-Based Quality Management Summit June 3-4th, 2021 On 3rd -4th June 2021, biopharma and medical device companies are invited to attend the Live Streaming of the Risk-Based Quality Management Summit. The event is hosted by Dynamic Global Events (“DGE”), a Life Science Leader in organizing B2B Events. The Global Event Company caters to the dynamic informational and networking needs of the Pharmaceutical, Biotechnology, Healthcare, Medical Devices, and allied industries. The 2-day event will start with the chairperson’s opening remarks followed by a keynote on World-Class Enterprise Risk Evaluation and Adaptive Monitoring provided Andy Lee, SVP, Head of Global Clinical Trials Operations at Merck Research Laboratories. Experts will share insights proactive risk management, quality my design and data monitoring. This Summit aims to discuss risk tolerance and agility in clinical trial oversight. The RBQM Summit will provide all the latest information that will help reduce the complexity and costs associated with clinical trials, cutting down the risks involved, to derive the maximum output from the R&D budget. The Risk-Based Quality Management Summit will include two sessions on COVID-19 with Phi Tat, Central Monitoring Manager, Pfizer (NASDAQ: PFE), and Jennifer Goewey, Associate Director, Risk Management-Central Monitoring, Janssen R&D, to address the impact of COVID19 on trials. The Summit will focus on complex issues, including: o How to design a comprehensive RBQM master plan on Streamline a “culture of quality” for proactive risk management to Discern the realities of applying Six Sigma to clinical research to Assess the situation when thresholds are exceeded and whether subsequent data are still valid to Evaluate remote monitoring of data and examine changes in clinical trial landscape post COVID-19 o Exacting a risk-based audit strategy and prepare to ensure inspection readiness The distinguished speaking faculty of the Summit consists of 15 imminent influencers from the pharma industry and risk-management experts. Andy Lee, Merck Research Laboratories, SVP, Head of Global Clinical Trials Operations; Andy Lawton, Risk-Based Approach Ltd, Consultant; Angela Repa, bluebird bio (NASDAQ: BLUE), Senior Director, Proactive Clinical Excellence; Anne Lawrence, AbbVie (NASDAQ: ABBV), Executive Director Site Management Operations; Celeste Gonzalez, Boston Scientific, Principal Specialist, Clinical Quality Assurance and Compliance; Shawntel Swannack, GSK (NASDAQ: GSK), Central Monitoring, to name a few. In these uncertain times, this Summit offers in depth and fresh perspectives on RBQM. It will provide an opportunity for World-Class Risk Evaluation and Adaptive Integrated Monitoring that will help conserve energy and resources and maintain agility in clinical trial oversight. For more information regarding the event, please visit https://ibn.fm/6bglf

• Consequences of novel Coronavirus infection on brain health are significant, requiring frequent brain monitoring
• Brain diagnostics in infected patients extremely limited due to their severe physical illnesses; traditional EEG time consuming, exposes frontline workers to virus transmission risk
• BRSF’s sanitary disposable NeuroCap(TM) helps health care workers get quick, reliable insights into patient’s condition while minimizing cross-contamination risk

Brain Scientific (OTCQB: BRSF), a commercial-stage healthcare company providing next-gen solutions to the neurology market, is poised to offer a response to brain diagnostic challenges in the hospitals’ red zones amid the pandemic. As the Company describes in one of the recent articles published on the website, the consequences of the COVID-19 pandemic on brain health are significant (https://ibn.fm/fhYxm).

While respiratory damage of novel Coronavirus is well reported, debilitating and even deadly neurological conditions may be affecting far more people infected with the virus. As the pandemic unravels and we learn more about the COVID-19, it is becoming clear that, although COVID-19 does not appear to directly attack nerve tissue, it is neurologically damaging. It is known to cause neurological injury in 1 out of 7 patients hospitalized with the infection (https://ibn.fm/aTUhK). The list of neurological diseases associated with COVID-19 infection is long and includes encephalopathy, Guillain-Barré syndrome, hemorrhagic stroke, ischemic stroke, meningoencephalitis, paralysis, and seizures. A growing body of evidence suggests that COVID-19 can have serious and potentially long-lasting effects on the brain — as many as 1 in 3 COVID-19 survivors experience neurological or a mental health disorder within six months of the infection (https://ibn.fm/Bop48).

COVID-19 appears to cause neurological injury through three mechanisms, including hypoxemia — the state of very low blood oxygen levels causing encephalopathy and neurological damage; immune dysfunction causing “cytokine storm” and blood clots.

Neurological conditions associated with COVID-19 are challenging to diagnose. For example, the diagnosis of encephalopathy, one of the most frequently occurring neurological conditions in COVID-19, is mainly clinical and heavily hindered by the severe physical illnesses of hospitalized infected patients. Investigative procedures such as MRI, lumbar puncture and cerebrospinal fluid analysis are complicated to perform on ICU patients that are on supportive care measures such as mechanical ventilation and supplemental oxygenation.

The quest for a diagnostic procedure that may offer a response in this extremely difficult and limiting setting is still ongoing – but EEG may be able to offer a solution.

EEG could be a potentially helpful study to conduct on patients with suspected COVID-19 encephalopathy. Bedside EEG testing may reveal occult, subclinical seizure activity that would otherwise go unveiled. Still, traditional EEG testing is a time-consuming task that requires placing electrodes and measuring the patient’s head, which all prolongs exposure of frontline health workers to the deadly virus.

When fighting a highly contagious disease, disposable technology is vital. This is where NeuroCap(TM) and NeuroEEG(TM), the Company’s two FDA-cleared devices, can help. They offer cost-efficient, portable neurological monitoring. With sanitary, disposable EEG caps, BRSF’s revolutionary solution helps health care workers get a quick, reliable picture of a patient’s condition while ensuring that the virus is not spread through equipment. BRSF’s EEG caps designed for single use are also easy to place – within minutes – which helps shorten person-to-person exposure, minimizing cross-contamination risk between staff and patients.

For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF